CareDx Q3 revenue $67.2M (-15% YoY); net loss $23.5M; raises FY2023 guidance to $274-278M

CareDx, Inc.

2023-Q3 EPS reported -$1.34 revenue$214,755,000

Revenue $67.2M (-15% YoY); testing services $47.8M (-26% YoY).
Net loss $23.5M ($0.43 loss per share) vs $16.9M loss ($0.32 loss per share) in Q3 2022; non-GAAP loss $9.6M.
Adjusted EBITDA loss $10.9M, compared to loss $2.5M in Q3 2022.
Raised full-year 2023 revenue guidance to $274-278M from prior outlook.
SEC concluded inquiry with no enforcement action; Medicare coverage for HeartCare and AlloSure Lung.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CareDx, Inc. reported the third quarter ended September 30, 2023 results: revenue $67.2 million, net income $23.5 million, EPS $0.43. Guidance raised.

Period: the third quarter ended September 30, 2023
Revenue: $67.2 million
Net income: $23.5 million
EPS: $0.43
Guidance: raised
Result: reported results

Exact text from the filing

for transplant patients and caregivers -- today reported financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Highlights • Reported revenue of $67.2 million, an increase of 7% over the second quarter of 2023, excluding approximately $7.8 million related to Medicare claims billing that were held over from the first quarter of 2023 and

View on SEC.gov

Browse all earnings releases →

CareDx, Inc. filing history →

Source: SEC EDGAR

accession 0001217234-23-000224

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.